TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM.
$9,042,149
| Recipient | INTRAVACC B.V. UEI RY3NEWMNZA63 |
|---|---|
| Award ID | 75N93020C00037 |
| Award amount | $9,042,149 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AJ12 |
| Start date | Sep 1, 2020 |
| End date | May 31, 2026 |
| Place of performance | — |
| Record updated | Aug 20, 2026 |
View the official award record
More awards won by INTRAVACC B.V.
DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA BASED ON OUTER MEMBRANE VESICLES COMBINED WITH SUSTAINED-RELEASE MICROSPHERES CONTAINING RECOMBINANT HUMAN INTERLEUKIN-12.
Department of Health and Human Services · $6,612,767 · Sep 21, 2022
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids